https://scholars.lib.ntu.edu.tw/handle/123456789/458224
標題: | Inhibition of metastatic potential in breast carcinoma in vivo and in vitro through targeting VEGFRs and FGFRs | 作者: | Chien M.-H Lee L.-M Hsiao M LING-HUNG WEI Chen C.-H Lai T.-C KUO-TAI HUA Chen M.-W Sun C.-M Kuo M.-L. |
公開日期: | 2013 | 卷: | 2013 | 起(迄)頁: | 718380 | 來源出版物: | Evidence-based Complementary and Alternative Medicine | 摘要: | Angiogenesis and lymphangiogenesis are considered to play key roles in tumor metastasis. Targeting receptor tyrosine kinases essentially involved in the angiogenesis and lymphangiogenesis would theoretically prevent cancer metastasis. However, the optimal multikinase inhibitor for metastasis suppression has yet to be developed. In this study, we evaluated the effect of NSTPBP 0100194-A (194-A), a multikinase inhibitor of vascular endothelial growth factor receptors (VEGFRs)/fibroblast growth factor receptors (FGFRs), on lymphangiogenesis and angiogenesis in a mammary fat pad xenograft model of the highly invasive breast cancer cell line 4T1-Luc+. We investigated the biologic effect of 194-A on various invasive breast cancer cell lines as well as endothelial and lymphatic endothelial cells. Intriguingly, we found that 194-A drastically reduced the formation of lung, liver, and lymph node metastasis of 4T1-Luc+ and decreased primary tumor growth. This was associated with significant reductions in intratumoral lymphatic vessel length (LVL) and microvessel density (MVD). 194-A blocked VEGFRs mediated signaling on both endothelial and lymphatic endothelial cells. Moreover, 194-A significantly inhibited the invasive capacity induced by VEGF-C or FGF-2 in vitro in both 4T1 and MDA-MB231 cells. In conclusion, these experimental results demonstrate that simultaneous inhibition of VEGFRs/FGFRs kinases may be a promising strategy to prevent breast cancer metastasis. ? 2013 Ming-Hsien Chien et al. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/458224 | ISSN: | 1741-427X | DOI: | 10.1155/2013/718380 | SDG/關鍵字: | 1 (2 cyclohexenylethyl) 2 [2 (3,3 diphenylpropyl) 2h indazole 6 yl] 1h benzo[d]imidazole 5 carboxylic acid; antineoplastic agent; fibroblast growth factor 2; fibroblast growth factor receptor; nstpbp 0100194 a; protein tyrosine kinase inhibitor; sorafenib; sunitinib; unclassified drug; vasculotropin C; vasculotropin receptor; angiogenesis; animal cell; animal experiment; animal model; animal tissue; antiangiogenic activity; antineoplastic activity; area under the curve; article; breast carcinoma; cancer cell culture; cancer inhibition; cell death; cell migration; cell proliferation; controlled study; cytotoxicity; drug blood level; drug efficacy; endothelium cell; female; human; human cell; in vitro study; in vivo study; liver metastasis; lung metastasis; lymph node metastasis; lymph vessel; lymph vessel endothelium; lymphangiogenesis; maximum plasma concentration; metastasis inhibition; metastasis potential; microvasculature; molecularly targeted therapy; mouse; nonhuman; priority journal; signal transduction; single drug dose; time to maximum plasma concentration; tumor invasion; tumor vascularization; tumor xenograft; umbilical vein endothelial cell |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。